ADAM9 and hepatocellular carcinoma: Recently, we discovered that regorafenib upregulates mMICA to a greater extent than sorafenib, suppressing ADAM9 in hepatoma cells [15], confirming the role of ADAM9 as an immunotherapeutic target.